Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Jennerex, Inc.
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
October 28th, 2008
Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) announced the completion of treatment for the first patient cohort in the Phase 1 cancer clinical trial of its targeted poxvirus JX-594, delivered by intravenous (IV) infusion. No significant toxicities were reported, and treatment was well-tolerated. The Phase 1 IV trial involves treatment of patients with advanced, metastatic solid tumors refractory to standard therapy. Patients receive treatment at one of five dose levels in a sequential dose-escalating design; the first cohort has now been treated safely. Once the maximum tolerated dose is defined, an additional three to six patients will be enrolled at that dose...
Source: Cancer Weekly (2008-10-28)
|
